- Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum.
- Shares recently hit a new 3-year high.
- Analyst sentiment is mixed with price targets ranging from $17 to $30.
- Investor focus has shifted from ADPT’s technology to its business execution, with technical indicators and momentum supporting continued attention.